Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial

Diabetes Technology & Therapeutics
Jian ZhouWeiping Jia

Abstract

Dyslipidemia is commonly seen in patients with type 2 diabetes mellitus (T2DM). The current study sought to compare the effects of nateglinide and acarbose, two antihyperglycemic agents, on both fasting and postprandial lipid profiles in Chinese subjects with T2DM. For this multicenter, open-label, randomized, active-controlled, parallel-group study, 103 antihyperglycemic agent-naive patients with T2DM were recruited from four hospitals in China. In total, 85 subjects (44 in the nateglinide group, 41 in the acarbose group) with a known complete lipid profile underwent the entire clinical trial and were included in the final analysis. Serum was collected in the fasting state and 30 and 120 min after a standardized meal (postprandial states) to measure the baseline lipid profiles; the same testing was performed upon completion of a 2-week course of nateglinide (120 mg three times a day) or acarbose (50 mg three times a day). Fasting triglyceride (TG) levels were significantly reduced by both nateglinide and acarbose (P<0.001), with acarbose providing a significantly more robust improvement (vs. nateglinide, P=0.005). Additionally, the TG levels at both postprandial times were significantly reduced by acarbose (P<0.001 at 30 min a...Continue Reading

References

Jan 1, 1996·Diabetic Medicine : a Journal of the British Diabetic Association·J L Chiasson
Oct 13, 1998·Diabetes Research and Clinical Practice·S KadoN Nagata
Jun 16, 1999·Diabetes Research and Clinical Practice·R ScottT Welborn
Dec 7, 2002·Diabetes/metabolism Research and Reviews·Juha VakkilainenMarja-Riitta Taskinen
Jul 20, 2007·JAMA : the Journal of the American Medical Association·Sandeep BansalPaul M Ridker
Sep 18, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Tomoya MitaRyuzo Kawamori
Feb 21, 2009·Nature Clinical Practice. Endocrinology & Metabolism·Arshag D Mooradian
Mar 16, 2013·World Journal of Diabetes·Yuichi KojimaToru Hiyoshi

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.